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Identification of novel targets in cancer immunotherapy
is needed to address the significant number of patients
that either do not respond to current therapies or
encounter unacceptable toxicities. The discovery of such
targets, including novel checkpoint regulators and the
counter-receptors for previously “orphan” checkpoints,
has been limited by a lack of a comprehensive collection
of proteins suitable for functional screening and meth-
ods for assessing their function in high-throughput.
We have generated a comprehensive library of substan-
tially all human extracellular proteins, encompassing
nearly every target for protein therapeutics. Our library
contains more than 5700 proteins, including secreted pro-
tein ligands and the extracellular domains of membrane-
bound receptors in soluble forms. The library proteins
represent therapeutic targets and in some cases may act as
therapeutics themselves. A portion of this library we call
the immunome contains ~500 proteins with structural fea-
tures characteristic of immune-activators and checkpoints
that we selected.
RIPPSSM technology is a robust method whereby Five-
Prime’s library of soluble secreted proteins can be tested
in vivo in virtually any disease model. Each cDNA repre-
senting a unique protein is administered to a cohort of
mice and results in high circulating levels of the encoded
protein. RIPPSSM also allows us to rapidly confirm activity
identified by other in vitro screening approaches. Here, we
have exploited RIPPSSM technology to screen for new
immuno-oncology therapeutics and targets for therapeutic
development. As positive controls we performed RIPPSSM
on CT-26 tumor-bearing mice using known agonists and
antagonists of the immune response, which resulted in
decreased or increased tumor growth, respectively. Subse-
quently, we screened over 250 immunome proteins by
RIPPSSM in the CT-26 tumor model and have identified
proteins that enhance and inhibit tumor growth and dis-
play changes in TIL (tumor-infiltrating lymphocyte) pro-
files. In addition, the immunome was screened in vitro for
the ability to modulate anti-CD3-stimulated human T cell
proliferation[1]. This screen identified a number of known
checkpoint regulators, which validated the assay, and
identified numerous novel co-inhibitory proteins – the
majority of which have no published link to immune cell
regulation. Proteins identified in the in vitro screens have
been validated using RIPPSSM and other in vivo methods.
These data demonstrate the power of our discovery plat-
form to discover and validate novel therapeutic targets
and protein therapeutics for immuno-oncology.
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